Tailoring treatment of rectal adenocarcinoma: Immunohistochemistry for predictive biomarkers

Anti-Cancer Drugs

Volumn 22, Issue 4, 2011, Pages 362-370

  Kapur, Payal ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biomarkers; chemoradioresistance; rectal adenocarcinoma

Indexed keywords

ANNEXIN; BETA TUBULIN; BIOLOGICAL MARKER; CALSENILIN; CARBONATE DEHYDRATASE IX; CYCLIN E; CYCLINE; CYCLOOXYGENASE 2; CYCLOPHILIN; CYTOKERATIN 18; DNA NUCLEOTIDYLEXOTRANSFERASE; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE PEROXIDASE; HEAT SHOCK PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUMICAN; MONOCLONAL ANTIBODY KI 67; NOTCH2 RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; SURVIVIN; THROMBOSPONDIN 2; THYMIDYLATE SYNTHASE; TROPOMODULIN; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RECTUM CARCINOMA; REVIEW; TISSUE MICROARRAY; TREATMENT RESPONSE;

ADENOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; NEOADJUVANT THERAPY; RADIATION TOLERANCE; RECTAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952985419     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283433764     Document Type: Review

References (61)

1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
2. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009;74:673-688.
3. Wong RK, Tandan V, De Silva S, Figueredo A. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007;2:CD002102.
4. Dalton WS, Friend SH. Cancer biomarkers - an invitation to the table. Science 2006;312:1165-1168. (Pubitemid 43801132)
5. Hendry JH, West CM. Apoptosis and mitotic cell death: their relative contributions to normal-tissue and tumour radiation response. Int J Radiat Biol 1997;71:709-719. (Pubitemid 27306026)
6. Ross GM. Induction of cell death by radiotherapy. Endocr Relat Cancer 1999;6:41-44. (Pubitemid 29197226)
7. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005;23:1826-1838. (Pubitemid 46217459)
8. Watanabe T, Komuro Y, Kiyomatsu T, Kanazawa T, Kazama Y, Tanaka J, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 2006;66:3370-3374.
9. Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, Park HW, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 2007;50:1342-1353. (Pubitemid 47472394)
10. Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 2009;75:489-496.
11. Allal AS, Kahne T, Reverdin AK, Lippert H, Schlegel W, Reymond MA. Radioresistance-related proteins in rectal cancer. Proteomics 2004;4:2261-2269. (Pubitemid 39025326)
12. Smith FM, Gallagher WM, Fox E, Stephens RB, Rexhepaj E, Petricoin EF III, et al. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg 2007;245:259-266. (Pubitemid 46151655)
13. Huerta S, Hrom J, Gao X, Saha D, Anthony T, Reinhart H, et al. Tissue microarray constructs to predict a response to chemoradiation in rectal cancer. Dig Liver Dis 2010;42:679-684.
14. Debucquoy A, Goethals L, Libbrecht L, Perneel C, Geboes K, Ectors N, et al. Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study. Int J Colorectal Dis 2009;24:129-138.
15. De Bruin EC, Van de Velde CJ, Van de Pas S, Nagtegaal ID, Van Krieken JH, Gosens MJ, et al. Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res 2006;12:6432-6436. (Pubitemid 44799715)
16. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
17. Baas IO, Van den Berg FM, Mulder JW, Clement MJ, Slebos RJ, Hamilton SR, et al. Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol 1996;178:264-267. (Pubitemid 26120990)
18. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-539.
19. Huerta S, Gao X, Saha D. Mechanisms of resistance to ionizing radiation in rectal cancer. Expert Rev Mol Diagn 2009;9:469-480.
20. Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;68:1455-1461. (Pubitemid 47176800)
21. Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol 2005;36:364-371. (Pubitemid 40591806)
22. Luna-Perez P, Arriola EL, Cuadra Y, Alvarado I, Quintero A. P53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann Surg Oncol 1998;5:203-208. (Pubitemid 28249307)
23. Spitz FR, Giacco GG, Hess K, Larry L, Rich TA, Janjan N, et al. P53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 1997;3:1685-1690. (Pubitemid 27444705)
24. Esposito G, Pucciarelli S, Alaggio R, Giacomelli L, Marchiori E, Iaderosa GA, et al. P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 2001;8:311-318. (Pubitemid 32422856)
25. Lin LC, Lee HH, Hwang WS, Li CF, Huang CT, Que J, et al. P53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 2006;15:211-216. (Pubitemid 46771194)
26. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381:713-716. (Pubitemid 26196573)
27. Tian H, Wittmack EK, Jorgensen TJ. P21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 2000;60:679-684. (Pubitemid 30094567)
28. Charara M, Edmonston TB, Burkholder S, Walters R, Anne P, Mitchell E, et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res 2004;24:3161-3167. (Pubitemid 39390968)
29. Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003;21:3391-3401. (Pubitemid 46594071)
30. Reerink O, Karrenbeld A, Plukker JT, Verschueren RC, Szabo BG, Sluiter WJ, et al. Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. Anticancer Res 2004;24:1217-1221. (Pubitemid 38624965)
31. Kim NK, Park JK, Lee KY, Yang WI, Yun SH, Sung J, et al. P53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol 2001;8:418-424. (Pubitemid 32524765)
32. Jakob C, Liersch T, Meyer W, Becker H, Baretton GB, Aust DE. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol 2008;14:1060-1066. (Pubitemid 351325006)
33. Willett CG, Warland G, Cheek R, Coen J, Efird J, Shellito PC, et al. Proliferating cell nuclear antigen and mitotic activity in rectal cancer: predictor of response to preoperative irradiation. J Clin Oncol 1994;12:679-682. (Pubitemid 24110904)
34. Desai GR, Myerson RJ, Higashikubo R, Birnbaum E, Fleshman J, Fry R, et al. Carcinoma of the rectum. Possible cellular predictors of metastatic potential and response to radiation therapy. Dis Colon Rectum 1996;39:1090-1096. (Pubitemid 26330516)
35. Tannapfel A, Nusslein S, Fietkau R, Katalinic A, Kockerling F, Wittekind C. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 1998;41:585-591. (Pubitemid 28275088)
36. Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992;52:5407-5411.
37. Fukunaga-Johnson N, Ryan JJ, Wicha M, Nunez G, Clarke MF. Bcl-2 protects murine erythroleukemia cells from p53-dependent and-independent radiation-induced cell death. Carcinogenesis 1995;16:1761-1767.
38. Kudrimoti M, Lee EY, Kang Y, Ahmed M, Mohiuddin M. Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers. J Ky Med Assoc 2007;105:18-22.
39. Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 2001;8:305-310. (Pubitemid 32422855)
40. Huerta S, Gao X, Livingston EH, Kapur P, Sun H, Anthony T. In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201. Surgery 2010;148:346-353.
41. Bonavida B, Khineche S, Huerta-Yepez S, Garban H. Therapeutic potential of nitric oxide in cancer. Drug Resist Updat 2006;9:157-173. (Pubitemid 44294871)
42. Huerta S, Baay-Guzman G, Gonzalez-Bonilla CR, Livingston EH, Huerta-Yepez S, Bonavida B. In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: involvement of AIF. Nitric Oxide 2009;20:182-194.
43. Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer 2005;104:2517-2521. (Pubitemid 41691576)
44. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147. (Pubitemid 38524883)
45. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008;51:1641-1648.
46. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-437. (Pubitemid 351744964)
47. Toiyama Y, Inoue Y, Saigusa S, Okugawa Y, Yokoe T, Tanaka K, et al. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. Clin Oncol (R Coll Radiol) 2010;22:272-280.
48. Smith FM, Reynolds JV, Kay EW, Crotty P, Murphy JO, Hollywood D, et al. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys 2006;64:466-472. (Pubitemid 43083434)
49. Grimminger PP, Brabender J, Warnecke-Eberz U, Narumiya K, Wandhofer C, Drebber U, et al. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer. J Surg Res 2010;164:e61-e66.
50. Giralt J, De las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005;74:101-108. (Pubitemid 40331866)
51. Kim JS, Kim JM, Li S, Yoon WH, Song KS, Kim KH, et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2006;66:195-200. (Pubitemid 44175651)
52. Spindler KL, Nielsen JN, Lindebjerg J, Brandslund I, Jakobsen A. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 2006;66:500-504. (Pubitemid 44332722)
53. Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer-is the water getting muddy? Acta Oncol 2010;49:278-286.
54. Okonkwo A, Musunuri S, Talamonti M, Benson A III, Small W Jr, Stryker SJ, et al. Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncol Rep 2001;8:497-500.
55. Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, et al. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 2003;46:192-202. (Pubitemid 36222619)
56. Negri FV, Campanini N, Camisa R, Pucci F, Bui S, Ceccon G, et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 2008;98:143-147.
57. Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, et al. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 2009;20:519-524.
58. Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O, et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009;27:2751-2757.
59. Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 2010;15:577-583.
60. Gavioli M, Bagni A, Piccagli I, Fundaro S, Natalini G. Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer: comparison between sonographic and histopathologic changes. Dis Colon Rectum 2000;43:1075-1083. (Pubitemid 30626139)
61. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19-23. (Pubitemid 27138353)